Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Active not recruiting 10Unknown 7Recruiting 4Completed 4Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 7

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Thoracic 7

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × lazertinib × Thoracic × Clear all
NCT05338619 2023-09-01

PLATINUM

Korea University Guro Hospital

Phase 2 Unknown
77 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Yonsei University

Phase 2 Unknown
129 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05716672 2023-02-08

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Pusan National University Hospital

Unknown
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Samsung Medical Center

Phase 2 Unknown
117 enrolled
Thoracic

Lung Neoplasms

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Seoul St. Mary's Hospital

Phase 2 Unknown
28 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05377788 2022-05-19

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Samsung Medical Center

Unknown
900 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05167851 2021-12-22

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Yonsei University

Phase 2 Unknown
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡